In April 2013, the first nonactivated four-factor prothrombin complex concentrate (4F-PCC; Kcentra, CSL Behring) was approved for urgentVKA reversal in patients with acute major bleeding.
While the incidence of the more deadly form of MRSA is declining, more needs to be understood about this infection so more cases can be prevented and those that occur can be properly diagnosed and successfully treated.
Chinese investigators conducted an observational retrospective case study of inpatients presenting at Guangdong General Hospital with acute fulminant myocarditis (AFM) between January 2001 and December 2010.
The results of a pair of landmark trials and a number of smaller studies suggest that use of human albumin as the initial resuscitation fluid in patients with severe sepsis or septic shock can importantly reduce its stubbornly high 30 percent death rate.
Despite its increasing prevalence, autoimmunity is still not categorized as a “disease,” and research to determine its cause remains hindered due to a lack of focus and funding.
Men have higher rates of death from preventable causes than women for many reasons, but research points mainly toward a failure to seek preventive care.
Thirty years after its quiet introduction, unabated global research interest in IVIG reflects just how much remains unknown about its therapeutic potential.
Attention to meeting payer requirements is good for the bottom line.
As chief operating officer of Protein Sciences, Dr. Mannon Cox has devoted her energy to creating a first-of-its-kind influenza vaccine. Now, she is setting her sights on developing vaccines for other diseases with the company’s innovative technology platform.
While there is no cure for this autoimmune disease, there are many treatments, including behavioral, medicinal and surgical, and research is ongoing.
While all IG products are comparably effective, they also have relevant differences that determine their tolerability by patients.